Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 13

1.

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.

Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, LeLeu X, Hulin C, Klein SK, Sonneveld P, Siegel D, Bladé J, Goldschmidt H, Jagannath S, Miguel JS, Orlowski R, Palumbo A, Sezer O, Rajkumar SV, Durie BG; International Myeloma Working Group.

Leukemia. 2012 Jan;26(1):149-57. doi: 10.1038/leu.2011.196. Epub 2011 Jul 29. Erratum in: Leukemia. 2012 May;26(5):1153. Nari, Hareth [corrected to Nahi, Hareth].

PMID:
21799510
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Treatment of relapsed and refractory multiple myeloma in the era of novel agents.

van de Donk NW, Lokhorst HM, Dimopoulos M, Cavo M, Morgan G, Einsele H, Kropff M, Schey S, Avet-Loiseau H, Ludwig H, Goldschmidt H, Sonneveld P, Johnsen HE, Bladé J, San-Miguel JF, Palumbo A.

Cancer Treat Rev. 2011 Jun;37(4):266-83. doi: 10.1016/j.ctrv.2010.08.008. Epub 2010 Sep 21. Review.

PMID:
20863623
[PubMed - indexed for MEDLINE]
3.

Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.

Richardson P.

Semin Hematol. 2005 Oct;42(4 Suppl 4):S9-15. Review.

PMID:
16344100
[PubMed - indexed for MEDLINE]
4.

Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens.

Zangari M, Fink L, Zhan F, Tricot G.

Clin Lymphoma Myeloma Leuk. 2011 Apr;11(2):228-36. doi: 10.1016/j.clml.2011.03.006. Epub 2011 Apr 8. Review.

PMID:
21575928
[PubMed - indexed for MEDLINE]
5.

Multiple myeloma.

Harousseau JL, Shaughnessy J Jr, Richardson P.

Hematology Am Soc Hematol Educ Program. 2004:237-56. Review.

PMID:
15561686
[PubMed - indexed for MEDLINE]
Free Article
6.

Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma.

Scott LJ, Lyseng-Williamson KA.

Drugs. 2011 Mar 26;71(5):625-49. doi: 10.2165/11206420-000000000-00000. Review.

PMID:
21443285
[PubMed - indexed for MEDLINE]
7.

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Plosker GL, Figgitt DP.

Drugs. 2003;63(8):803-43. Review.

PMID:
12662126
[PubMed - indexed for MEDLINE]
8.

Carfilzomib: in relapsed, or relapsed and refractory, multiple myeloma.

McCormack PL.

Drugs. 2012 Oct 22;72(15):2023-32. doi: 10.2165/11209010-000000000-00000. Review.

PMID:
22994535
[PubMed - indexed for MEDLINE]
9.

The treatment of relapsed and refractory multiple myeloma.

Richardson P, Mitsiades C, Schlossman R, Ghobrial I, Hideshima T, Chauhan D, Munshi N, Anderson K.

Hematology Am Soc Hematol Educ Program. 2007:317-23. Review.

PMID:
18024646
[PubMed - indexed for MEDLINE]
Free Article
10.

The role of immunomodulatory drugs in multiple myeloma.

Anderson KC.

Semin Hematol. 2003 Oct;40(4 Suppl 4):23-32. Review.

PMID:
15015893
[PubMed - indexed for MEDLINE]
11.

New therapies in multiple myeloma.

Merchionne F, Perosa F, Dammacco F.

Clin Exp Med. 2007 Sep;7(3):83-97. Epub 2007 Oct 3. Review.

PMID:
17972050
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.

Hagemeister FB.

Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. Epub 2002 Apr 12. Review.

PMID:
12042984
[PubMed - indexed for MEDLINE]
13.

Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.

Bladé J, Cibeira MT, Rosiñol L.

Acta Oncol. 2005;44(5):440-8. Review.

PMID:
16118077
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk